Shilu Di Pharmaceutical Co., Ltd (01244): Envida has been granted orphan drug status for the treatment of gastric cancer and gastroesophageal junction cancer.

China Finance and Economics App News, SiLuDi Pharmaceuticals (01244) announced that its commercial product Envida (generic name: Envorlig monoclonal antibody injection, original research code: KN035) has officially obtained orphan drug qualification for the indications of gastric cancer and gastroesophageal junction cancer. This is the third orphan drug indication successfully approved for Envida after indications for bile duct cancer and soft tissue sarcoma.